Scarica l'app Stockscreener
55.23
1.62%
-0.91
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$56.14
Aprire:
$55.82
Volume 24 ore:
15.47M
Relative Volume:
1.03
Capitalizzazione di mercato:
$187.24B
Reddito:
$45.44B
Utile/perdita netta:
$16.18B
Rapporto P/E:
15.20
EPS:
3.634
Flusso di cassa netto:
$9.21B
1 W Prestazione:
-2.18%
1M Prestazione:
+16.96%
6M Prestazione:
-39.21%
1 anno Prestazione:
-57.80%
Intervallo 1D:
$54.73
$56.08
Intervallo di 1 settimana:
$54.73
$57.35
Portata 52W:
$45.05
$138.22
Novo Nordisk Adr Stock (NVO) Company Profile
Nome
Novo Nordisk Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NVO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
55.23 | 249.45B | 45.44B | 16.18B | 9.21B | 3.634 |
|
LLY
Lilly Eli Co
|
727.21 | 665.99B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.43 | 430.51B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
212.56 | 376.28B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
129.73 | 248.60B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.71 | 209.94B | 63.43B | 16.42B | 14.72B | 6.49 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-13 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Downgrade | UBS | Buy → Neutral |
| 2025-07-31 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-30 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Aggiornamento | Kepler | Hold → Buy |
| 2025-03-03 | Downgrade | Stifel | Buy → Hold |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-12 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Neutral |
| 2023-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Iniziato | Argus | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2022-07-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Downgrade | UBS | Neutral → Sell |
| 2022-06-27 | Aggiornamento | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-04-25 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2022-04-12 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Downgrade | Liberum | Hold → Sell |
| 2021-12-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-07-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-05-11 | Downgrade | UBS | Buy → Neutral |
| 2020-05-04 | Iniziato | Cowen | Market Perform |
| 2020-03-16 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-11-18 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-30 | Downgrade | Jefferies | Hold → Underperform |
| 2019-06-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Iniziato | Exane BNP Paribas | Outperform |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2017-12-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
Mostra tutto
Novo Nordisk Adr Borsa (NVO) Ultime notizie
Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication - Benzinga
ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming DeadlinesNVO - cnhinews.com
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Novo Nordisk Slumps While Philips Shines In European ADRs - Finimize
NVO’s Debt-to-Equity Ratio at 0.59: What It Means for Novo Nordisk ADR’s Future - investchronicle.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.
Hims & Hers (HIMS) Stock Lawsuits: Investors Urged to Act - GlobeNewswire Inc.
Novo Nordisk A/S Class Action Lawsuit: Pomerantz Law Firm Reminds Investors of Upcoming Deadlines - AInvest
HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.
INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Using data models to predict Novo Nordisk A s (b Shares) Adrhedged stock movementBuy Signal & Weekly Stock Performance Updates - Newser
Reversal indicators forming on Novo Nordisk A s (b Shares) Adrhedged stockJuly 2025 Action & Daily Growth Stock Investment Tips - Newser
Can momentum traders help lift Novo Nordisk A s (b Shares) Adrhedged2025 Stock Rankings & Long-Term Safe Investment Plans - Newser
Is Novo Nordisk A s (b Shares) Adrhedged showing signs of accumulationJuly 2025 Institutional & Low Risk Entry Point Tips - Newser
Is Novo Nordisk A s (b Shares) Adrhedged still worth holding after the dipTrade Risk Assessment & Consistent Growth Equity Picks - Newser
Does Novo Nordisk A s (b Shares) Adrhedged fit your quant trading modelMarket Trend Summary & Detailed Earnings Play Alerts - Newser
Is Novo Nordisk A s (b Shares) Adrhedged stock ready for a breakoutMarket Risk Report & Verified Short-Term Plans - Newser
What moving averages say about Novo Nordisk A s (b Shares) Adrhedged2025 Top Gainers & Community Verified Swing Trade Signals - Newser
What’s next for Novo Nordisk A s (b Shares) Adrhedged stock priceEarnings Recap Report & Expert Approved Momentum Trade Ideas - Newser
Earnings visualization tools for Novo Nordisk A s (b Shares) AdrhedgedChart Signals & Precise Entry and Exit Recommendations - Newser
Using portfolio simulators with Novo Nordisk A s (b Shares) Adrhedged includedJuly 2025 Catalysts & Verified Momentum Stock Ideas - Newser
Novo Nordisk shares rise 1.58% premarket after board member Christina Law's ADR purchase. - AInvest
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons - The Manila Times
Novo Nordisk Board Member Christina Law Buys $0.8 Million in ADRs - AInvest
Novo Nordisk Board Member Christina Law Purchases ADRs Worth DKK 0.8 Million - MarketScreener
Technical signs of recovery in Novo Nordisk A s (b Shares) AdrhedgedPortfolio Risk Report & Real-Time Stock Entry Alerts - Newser
Novo Nordisk A s (b Shares) Adrhedged stock prediction for this weekJuly 2025 Final Week & Pattern Based Trade Signal System - Newser
Glenn Jorgensen @Glennjdk: "𝐖𝐞 𝐡𝐚𝐝 𝐦𝐨𝐫𝐞 𝐍𝐨𝐯𝐨 𝐍𝐨𝐫𝐝𝐢𝐬𝐤..." - eToro
Using data filters to optimize entry into Novo Nordisk A s (b Shares) Adrhedged2025 Top Decliners & Technical Entry and Exit Alerts - Newser
Novo Nordisk Adr Azioni (NVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):